Whole blood is supplied as a 4 - 8 ml frozen blood sample in a standard K2-EDTA tube (the anti-coagulation agent can be changed per customer request . Serum/Plasma is obtained from 8 ml of whole blood using standard blood fraction separation procedures (e.g. BD Biosciences serum/plasma collection tubes and protocols). The specimens are supplied as snap-frozen aliquots (0.5 - 5 ml) in standard cryovials. Subcellular fractions from blood (including viable frozen cells) can be prepared per customer request
Bone Marrow aspirates (0.5 - 3 ml) and/or bone marrow trephine biopsies (as available) are obtained from patients with hematologic malignancies. The specimens are snap-frozen and supplied in standard cryovials. Subcellular fractions from bone marrow aspirates (including viable frozen cells) can be prepared per customer request
Hematologic Oncology (leukemia, multiple myeloma, MDS): bone marrow and blood products
- Solid Oncology: viable and snap-frozen PBMC, whole fresh blood, cancer serum, cancer plasma
- Inflammation: whole blood PBMC, serum, plasma
- Normal Tissues: bone marrow (snap-frozen and FFPE, slides), PBMC (slides)
To inquire about the current availability of specimens or to investigate your custom project feasibility, contact our office or send us an inquiry via email.
APPLICATION: Signal transduction studies (RNA, protein, IHC analysis) using a new drug lead.
Leukemia (CLL, CML, ALL, AML):
Isolation of cancer PBMCs from fresh blood using a Ficoll-based protocol, and preparation of viable cells in DMSO-containing medium. Collection of matching cancer serum samples with extensive clinical information for each patient.
Myelodysplastic Syndrome (MDS):
Preparation of viable BMMCs, snap-frozen cell pellets and RNA. Collection of matching cancer serum samples and extensive clinical information for each patient.
CLL and MM:
Preparation of bone marrow FFPE (cells from aspirate and trephine biopsy specimens.
Multiple Myeloma (MM):
Preparation of BMMC FFPE blocks from isolated bone marrow mononuclear cells. Collection of matching cancer serum samples and extensive clinical information for each patient.